TOPIGEN Pharmaceuticals Inc.

November 28, 2006 08:30 ET

TOPIGEN's President and CEO to Present at BMO Capital Markets' Focus on Healthcare Conference

Update to Be Provided on Progress With Inhaled TPI-ASM8 and Other Proprietary Programs in Development

MONTREAL and PARSIPPANY, NJ--(CCNMatthews - November 28, 2006) - TOPIGEN Pharmaceuticals Inc., an emerging biopharmaceutical company specializing in developing treatments for respiratory diseases, today announced that Paul K. Wotton, Ph.D., President and Chief Executive Officer, will be presenting at BMO Capital Markets' Focus on Healthcare Conference. Recently, TOPIGEN announced positive results with its asthma candidate, inhaled TPI-ASM8, which the company believes is the first lung-specific RNA-targeted oligonucleotide therapy to demonstrate a significant therapeutic effect in the lungs in an established model of asthma. Dr. Wotton will provide an update on the development progress of inhaled TPI-ASM8 and other programs that apply TOPIGEN's unique multi-targeted approach to specifically block multiple inflammatory disease pathways.

The conference will take place at the Millennium Broadway Hotel in New York City from December 6-7, 2006. Dr. Wotton's presentation will take place on Wednesday, December 6th from 9:00 a.m.-9:30 a.m. EST, and he will be available for one-on-one meetings during the conference. For more information about the Focus on Healthcare Conference, please visit


TOPIGEN is a privately-held, clinical-stage biopharmaceutical company focused on developing new classes of inhaled drugs for respiratory disorders. TOPIGEN's pipeline includes small molecule and RNA-targeting therapeutics. The Company has two products currently undergoing Phase II trials and research programs uniquely focused on inhibiting multiple inflammatory pathways at the cellular site of lung inflammation. By topically targeting multiple affected airway receptors with its drugs, the Company expects to improve outcomes for many patients with respiratory diseases. This approach has shown promising preclinical and clinical results in inhibiting the underlying inflammation associated with many pulmonary conditions such as asthma, COPD and allergic rhinitis. For more detailed information on TOPIGEN visit

Contact Information